Although CA19-9 serum levels were better correlated with overall stage-wise tumor progression compared to DCLK1, further studies will be needed to assess whether increased serum expression of DCLK1 in stage I and II PDAC is a relevant predictor of metastatic progression, surgical and chemotherapeutic response, and patient survival. This evidence concerns the gene DCLK1 and neoplasm.